EGFR-amplified tumours tended to be primarily classical in both primary (16/20) and recurrence (16/19), and EGFR non-amplified tumours tended to be classical (14/21) and mesenchymal (7/21) in recurrence. This evidence concerns the gene EGFR and neoplasm.